Millions of older adults on Medicare prescription drug coverage could face steeper monthly costs in 2027, after the Trump administration confirmed it will wind down a temporary subsidy program that has helped offset premiums for the past two years. The announcement, made this week by the Centers for Medicare & Medicaid Services (CMS), marks a significant shift for the roughly 25 million Americans enrolled in standalone Medicare Part D drug plans, many of whom are now bracing for higher bills heading into 2027.
What Is Changing With the Medicare Part D Subsidy Program
The subsidy at the center of this decision is known as the Part D Premium Stabilization Demonstration. It was created by the Biden administration in 2024 to smooth out the financial disruption caused by changes under the 2022 Inflation Reduction Act, which capped out-of-pocket drug spending for Medicare beneficiaries and shifted more of the cost burden onto insurance companies. Because insurers were initially unsure how much more they would owe under the new rules, the demonstration project offered them extra federal funding to keep monthly premiums predictable for enrollees.
CMS has now determined that insurers have gathered enough experience with the revised benefit structure to price their plans independently, without additional federal support. As a result, the subsidy will be discontinued at the close of 2026, effectively ending it a year earlier than originally planned. The demonstration had initially been expected to run through 2027.
It is important to note that this change applies specifically to standalone Part D drug plans, not to the roughly 34 million people enrolled in Medicare Advantage plans that include bundled prescription drug coverage. Those plans are financed differently and are not directly affected by the end of this particular subsidy.
Why the Subsidy Program Is Ending
CMS Administrator Dr. Mehmet Oz addressed the decision directly, framing it as a return to a more sustainable insurance market rather than a cost-cutting measure aimed at beneficiaries. He said the agency is “stabilizing the market” so that continued federal support is no longer necessary, adding that premiums are expected to rise by less than $10 for most Medicare recipients, with some beneficiaries potentially seeing lower premiums depending on their chosen plan. He also pointed to broader efforts to reduce drug costs, including expanded government drug-pricing negotiations and a program offering GLP-1 medications for $50 a month to eligible seniors.
Federal officials maintain that the overall financial impact on beneficiaries will be minimal. However, health policy researchers caution that the removal of billions of dollars in annual support could still translate into noticeably higher premiums for a meaningful share of enrollees, particularly those on fixed incomes.
How Much More Could Beneficiaries Pay in 2027
The subsidy program has played a measurable role in keeping Part D premiums low. According to the healthcare research nonprofit KFF, beneficiaries paid an average of about $36 a month for standalone drug coverage in 2026 with the subsidy factored in. Data from the federal Medicare Payment Advisory Commission (MedPAC) shows the subsidy reduced the average monthly premium by roughly $26 in 2025 and by about $16 in 2026. Without that support, premiums for some plans may climb well beyond those averages next year.
Juliette Cubanski, director of KFF’s program on Medicare policy, noted that some Part D enrollees could face relatively steep premium increases for drug coverage in 2027 now that the enhanced financial support is gone, though she emphasized that plan-specific premium amounts are not yet confirmed. Because pricing varies significantly from one insurer and one region to another, the exact increase any individual beneficiary experiences will depend heavily on which plan they choose.
CMS has released some early figures tied to 2027 plan bids. The national average monthly bid amount, a figure used to calculate government subsidy payments to insurers, will be $296.05 for 2027. The national base beneficiary premium, a benchmark used in individual plan premium calculations, is set at $41.33 for the coming year. A provision of the Inflation Reduction Act limits how quickly that base premium can grow, capping annual increases at no more than 6 percent through 2029, which offers at least some protection against runaway cost growth.
What This Means for the Out-of-Pocket Spending Cap
One important distinction is that this policy change does not affect the annual out-of-pocket spending cap for Medicare drug costs. That cap, a separate protection established under the Inflation Reduction Act, limits how much beneficiaries with standalone Medicare drug coverage spend on prescriptions over the course of a year regardless of their monthly premium. The cap was set at $2,100 in 2026 and is projected to rise to $2,400 in 2027. So while monthly premiums may increase for some enrollees, the ceiling on total annual prescription spending remains intact and continues to adjust upward as part of separate, ongoing policy.
Public Interest and Political Reaction
The timing of this decision has drawn significant attention because it lands in a high-stakes midterm election year, and CMS has said final 2027 premium details will not be released until mid- to late September, with beneficiaries able to shop for new plans during Medicare’s open enrollment period from October 15 through December 7. That window overlaps closely with the November elections, meaning many older adults will learn how much more they may owe just weeks before heading to the polls.
Cost of living remains a top concern for voters, and older Americans, who vote in high numbers and are often on fixed incomes, are particularly sensitive to changes in monthly expenses. Democratic officials have criticized the move, framing it alongside other recent federal healthcare changes, including reductions to Medicaid funding and the expiration of enhanced subsidies for Affordable Care Act marketplace plans. Senate Minority Leader Chuck Schumer called the decision to raise prescription drug costs for seniors “heartless” and said it was made by choice rather than necessity.
The insurance industry has responded more cautiously. AHIP, the leading lobbying group representing health insurers, said it was still evaluating the announcement, while noting that member companies remain committed to keeping Part D coverage as affordable as possible despite rising drug costs industry-wide. Insurers that offer Medicare Part D plans include major national carriers such as UnitedHealth Group, Humana, and Aetna.
Latest Updates and What Comes Next
As it stands, CMS has confirmed the subsidy demonstration will end this year, and the agency has published preliminary 2027 bid figures, including the national average monthly bid amount and base beneficiary premium mentioned above. However, there is no official confirmation yet on exactly how individual plan premiums will change, since insurers set their own final rates plan by plan. CMS has indicated that detailed 2027 premium and plan information will be released in September, giving beneficiaries several weeks to compare options before open enrollment begins.
Because premium changes will vary widely depending on the insurer, plan, and region, beneficiaries will not have a clear picture of their own costs until that information becomes available. Anyone currently enrolled in a standalone Medicare Part D plan may want to pay close attention to plan comparison tools and official CMS communications once the fall enrollment window opens, since switching to a different plan during that period is one of the few ways enrollees can directly manage how much they pay.
Final Thoughts
The end of the Part D Premium Stabilization Demonstration represents one of the more consequential Medicare policy shifts heading into 2027, even as officials and independent analysts disagree on how large the impact will ultimately be. While the administration maintains that most beneficiaries will see only modest premium changes, and some may even pay less, health policy experts warn that a subset of enrollees in standalone plans could see more significant increases once federal support is fully removed. With final premium details still months away and open enrollment arriving alongside a competitive midterm election season, Medicare prescription drug coverage costs are likely to remain a closely watched issue for seniors, policymakers, and voters alike well into the fall.
Stay tuned for updates as CMS releases final 2027 Medicare Part D premium details, and share your thoughts in the comments below.